LOS ANGELES, CA, Oct 11, 2013 (Marketwired via COMTEX) -- SK3 Group, Inc. (OTC
Pink: SKTO) ("the Company") announced that it plans to release 3rd quarter
results by month's end.
As part of the Company's effort to enhance its operations, management is
improving its reporting efforts and as a result will issue the 3rd quarter
results early. "We are continuing to bolster our managerial services and as a
result we will be better able to report to our shareholders results of
operations for the 3rd quarter and 9 months ending September 30, 2013, earlier
than required," stated Mr. Artemus Mayor, President of SK3 Group, Inc. "We will
also post to our web-site a pre-recorded conference call with the officers of
the Company shortly after the reporting of our 3rd quarter fiscal results," Mr.
Mayor added. "While we had said before we may do a management conference call
earlier in the month, we think it prudent to wait until after we have released
the financials so that management can better respond to that information and any
investor questions relating thereto."
For the near term, the Company's milestones include increasing revenues,
steadily collecting receivables, expanding product offerings, enhancing the team
and its capabilities, and cleaning up various corporate issues such as the
CUSIP, dividend, name change, audits, and other operational issues.
"The Company had a terrific third quarter and when the financial results are
released investors will see that we have continued in our long term focus to
collect receivables and enhance revenues, increase cash on hand while investing
intelligently in the business, focus on personnel and acquiring the right
business relationships, and otherwise expand the Company's role in the medical
marijuana space," said Kevin Allyn, the Company's Chairman. "We are looking
forward to sharing more details with our investors on each of these points in
the near future. But investors will be able to measure our long term progress by
how we fare against our milestones."
Previously the Company announced, that its wholly owned subsidiary Medical
Greens announced that it has obtained the exclusive license for Dharmanol(TM)
for the State of California. Dr. Charles Apel, of Berkeley Bio-Organic Research
Laboratories has developed a proprietary technology to extract, stabilize, and
preserve the medicinal cannabinoids found in hemp and marijuana in their
non-psychoactive form. This technology allows patients to consume cannabinoid
medicine without any of the "high" or "stoned" effects.
Dharmanol(TM) (pronounced DAR-mah-nol) will be available in two forms: low-dose
non-psychoactive tablets and high-doses. The low-dose non-psychoactive tablets
can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid
system, an internal system which controls and regulates many other bodily
systems such as immune response. Much research has shown that there is
substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid
system with cannabinoids, causing the other systems to work as they should.
